HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
Heron Therapeutics (HRTX) PT Raised to $66 at Needham & Company
June 21, 2018 3:48 PM EDTNeedham & Company raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $66.00 (from $42.00) while maintaining a Buy rating.
Analyst Serge Belanger commented, "HRTX reported positive results from two Phase 2b studies in total knee arthroplasty (TKA) and breast augmentation where HTX-011 successfully... More
Heron Therapeutics (HRTX) PT Raised to $54 at Cowen; Sees HTX-011 as $1B+ Opportunity
June 21, 2018 1:15 PM EDTCowen raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $54.00 (from $48.00) while maintaining an Outperform rating after the company announced positive Phase IIb data in TKA and breast augmentation demonstrating superior pain control and opioid reduction compared to placebo and generic bupivacaine. In addition HTX-011... More
Heron Therapeutics (HRTX) PT Raised to $51 at Jefferies
June 21, 2018 11:39 AM EDTJefferies raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $51.00 (from $38.00) while maintaining a Buy rating.
... MoreTwo More Positive HTX-011 Studies Supports Bullish Heron Therapeutics (HRTX) Thesis - Cantor Fitzgerald
June 21, 2018 10:47 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $40 price target on Heron Therapeutics (NASDAQ: HRTX) announced positive top-line results from two additional studies which will support the NDA filing for HTX-011 and expand the commercial opportunity for the drug.
"This... More
Heron Therapeutics (HRTX) PT Raised to 'Street High' $80 at Evercore ISI
June 21, 2018 10:23 AM EDTEvercore ISI raised its price target on Heron Therapeutics (NASDAQ: HRTX) to a 'Street High' $80.00 (from $56.00) while maintaining an Outperform rating.
Analyst Josh Schimmer with the rating news.
... More